Alkeus’ lead molecule, gildeuretinol (ALK−001), has shown tremendous promise in addressing this critical issue

The formation of toxic vitamin A dimers, or clumps, in the eye is a key factor in the progression of several degenerative eye diseases. These dimers contribute to irreversible retinal damage, leading to vision loss and blindness. Recognizing the need for a new treatment approach, Alkeus Pharmaceuticals set out to develop a molecule that could mitigate this toxic dimerization process. Alkeus’ lead molecule, gildeuretinol (ALK−001), has shown tremendous promise in addressing this critical issue. ALK−001 is designed to reduce the formation of harmful vitamin A dimers, potentially slowing or even preventing the progression of degenerative eye diseases. By targeting the root cause of retinal damage, ALK−001 offers a groundbreaking approach to preserving vision and improving the quality of life for patients.